Company
CatalYm GmbH
CatalYm GmbH has 1 drug tracked on RxWires: 1 in Phase 2.
Pipeline
| Drug | Phase | Indication |
|---|---|---|
| Visugromab RDE (recommended dose for expansion) | Phase 2 | Unresectable or Metastatic Hepatocellular Carcinoma |
Latest
No recent events.
Follow CatalYm GmbH on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.